HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Parsol 1789

This article was originally published in The Rose Sheet

Executive Summary

Parsol 1789: Hoffmann-La Roche requests that FDA complete by Oct. 1 the necessary administrative functions that would allow for interim marketing of UVA sunscreen Parsol 1789 (avobenzone) in a May 21 letter. The letter responds to a May 9 letter from FDA stating that the agency will allow use of Parsol 1789 in combination with some Category I sunscreens and that interim marketing would be permitted only after a Federal Register notice and comment period process ("The Rose Sheet" June 3, p. 3). Hoffmann-La Roche additionally requested: interim marketing of Parsol 1789 combinations that have already been NDA-approved and have U.S. marketing experience; and an exemption from the IND regs for clinical testing of avobenzone combinations proposed for inclusion in the monograph...

You may also be interested in...

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Chart: Weekly Trademark Review -- Nov. 2, 2010

Weekly Trademark Review




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts